H.C. Wainwright analyst Vernon Bernardino started Geron with a Buy rating and $4 price target. The analyst says he's bullish on the shares based on the return of global rights to imetelstat from Janssen, which he thinks has the potential to result in higher returns, the potential of imetelstat to decrease red blood cell transfusion dependence in patients suffering with low- or intermediate-1 risk myelodysplastic syndromes, and the potential of imetelstat to have a disease-modifying effect in patients suffering with myelofibrosis. Geron's potential for increased returns from full global rights to imetelstat is underappreciated by investors, Bernardino tells investors in a research note.